Agilvax, Inc.
virus-like particle (VLP) immunotherapy targeting cancer stem cells in triple-negative breast cancer
- Sector
- Biotech
- Headquarters
- Albuquerque, NM
- Founded
- 2011
- Latest Form D
- $500K, May 2018
- Total capital
- $5.4M
- Federal grants
- $3.7M
- 4 awards · 2016–2020
- Rank in peer group#257 of 514
- Private capital raised
- $1.6M
- 2 Form D · last May 2018
- 102 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 3 pending · first 2020
- Rank in peer group#109 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer$1.2M
- Federal grantHealth and Human S · Phase II · A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer$2M
- Federal grantHealth and Human S · Phase II · A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer$299K
- Private capital raisedForm D · SEC · 2nd filing$500K
- Federal grantHealth and Human S · Phase I · Development of a VLP-based RSV Vaccine Targeting Pre-fusion F-Protein$287K
- Private capital raisedForm D · SEC · 1st filing$1.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#257 · top 50%
- Granted patents#109 · top 21%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Federica PericleResearcherExecutive Officer, DirectorLinked by 1 patent · $585K in grants as PI
- Joseph PattiResearcherExecutive Officer, DirectorLinked by $3.2M in grants as PI
- Bill C EnloeDirectorNamed in SEC Form D filings
- Brad ValeDirectorNamed in SEC Form D filings
- Brian BirkExecutive Officer, DirectorNamed in SEC Form D filings
- Debora E RamirezExecutive OfficerNamed in SEC Form D filings
Show all 11 people
- Dee BresciaExecutive OfficerNamed in SEC Form D filings
- Ebetuel C PallaresDirectorNamed in SEC Form D filings
- Faith CharlesDirectorNamed in SEC Form D filings
- Stuart RoseDirectorNamed in SEC Form D filings
- Waneta TuttleDirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 6- PendingCompositions And Methods Related To Xct AntibodiesUSPTOApplication 17609442
- GrantedCOMPOSITIONS AND METHODS RELATED TO xCT ANTIBODIESUSPTOUS 11,059,901
- GrantedCOMPOSITIONS AND METHODS RELATED TO xCT PEPTIDESUSPTOUS 11,040,223
Show all 6 patent records
- Compositions And Methods Related To Xct AntibodiesJul 7, 2022 · Application 17609442Pending
- COMPOSITIONS AND METHODS RELATED TO xCT ANTIBODIESJul 13, 2021 · US 11,059,901Granted
- COMPOSITIONS AND METHODS RELATED TO xCT PEPTIDESJun 22, 2021 · US 11,040,223Granted
- COMPOSITIONS AND METHODS RELATED TO xCT PEPTIDESMar 17, 2020 · US 10,588,953Granted
- Compositions And Methods Related To Xct PeptidesApplication PCTUS2020032121Pending
- Compositions And Methods Related To Xct AntibodiesApplication PCTUS2018030276Pending
Related companies, and why
- RegulonixSimilar federal contract value in Biotech · null in contracts
- 4E THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Hillhurst Biopharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- RESOLUTE SCIENCE, INC.Similar federal contract value in Biotech · null in contracts
- ZYWIE LLCSimilar federal contract value in Biotech · null in contracts
- ORPRO THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .